• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CVRx Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    3/3/26 5:15:34 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care
    Get the next $CVRX alert in real time by email
    false 0001235912 0001235912 2026-02-27 2026-02-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT 

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): February 27, 2026

     

     

     

    CVRx, Inc. 

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-40545   41-1983744
    (State or other jurisdiction of
    incorporation)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification No.)

     

    9201 West Broadway Avenue, Suite 650 

    Minneapolis, MN 55445 

    (Address of principal executive offices) (Zip Code)

     

    (763) 416-2840 

    (Registrant’s telephone number, including area code)

     

    N/A 

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange
    on which registered
    Common stock, par value $0.01 per share   CVRX   The Nasdaq Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On February 27, 2026, at the same time as the Compensation Committee (the “Committee”) of the Board of Directors of CVRx, Inc. (the “Company”) approved annual equity awards for the Company’s executive officers, the Committee also approved an incremental equity award in the form of performance stock units (“PSU”) specific to a cumulative revenue goal for the fiscal 2026-2027 performance period. The PSUs were granted to all executive officers based on the Committee’s review of information regarding the retentive value of existing equity awards, criticality of achievement of near-term objectives and expected levels of future contributions. The grant date value of the PSUs granted to the named executive officers was equal to three-fourths of the value of their annual long-term incentives for fiscal 2026.

     

    The PSUs are eligible to vest based on achievement of the cumulative revenue goal, with the amount of PSUs that can be earned ranging from 50% of target for performance at the threshold level to 200% of target for performance at the maximum level. The cumulative revenue goal is not disclosed due to its competitive sensitivity; however, the Committee believes the target goal represents meaningful revenue growth. Any earned PSUs will vest and be settled in shares of the Company’s common stock as follows: 50% upon certification of the cumulative revenue goal following the performance period and the remaining 50% on December 31, 2028, in each case subject to the executive’s continued employment through such dates, subject to certain provisions for accelerated or continued vesting in the event of death, disability, termination without cause or a “double trigger” event following a change in control, with the PSUs converting to time-based restricted stock units at the greater of the target or actual level of performance upon a change in control. The form of Performance Stock Unit Agreement is filed as Exhibit 10.1 hereto.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit
    No.
      Description
    10.1   Form of Performance Stock Unit Agreement (Executives – 2026-2027 Cumulative Revenue) pursuant to 2021 Equity Incentive Plan
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CVRx, Inc.
       
    Date: March 3, 2026 By: /s/ Jared Oasheim
        Name: Jared Oasheim
        Its: Chief Financial Officer

     

     

     

    Get the next $CVRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVRX

    DatePrice TargetRatingAnalyst
    5/9/2025$7.00Neutral → Underweight
    Analyst
    1/14/2025Mkt Perform → Outperform
    William Blair
    9/10/2024$14.00Overweight
    Cantor Fitzgerald
    7/11/2024$18.00 → $12.00Buy
    Lake Street
    5/1/2024$30.00 → $23.00Buy
    Craig Hallum
    5/1/2024Outperform → Mkt Perform
    William Blair
    5/1/2024$36.00 → $13.00Overweight → Neutral
    JP Morgan
    1/31/2023$20.00Buy
    Lake Street
    More analyst ratings

    $CVRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

    MINNEAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on Wednesday, June 10, 2026. The Company's presentation will begin at 8:00 a.m. (ET). A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time. About CVRx, Inc. CVRx i

    5/27/26 4:30:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx to Present at the William Blair 46th Annual Growth Stock Conference

    MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that the management team will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026. The Company's presentation will begin at 10:40 a.m. (CT). A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time. About CVRx, Inc. CVRx is a

    5/20/26 4:30:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy

    MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Humana has issued a Medicare Advantage coverage policy for Barostim therapy, effective May 1, 2026. Humana, a national health insurance company with the second largest Medicare Advantage program in the U.S., provides coverage to approximately 5.2 million Medicare Advantage members across 46 states. The new policy covers Barostim for patients meeting its current FDA-approved indication as well as patients enrolled

    5/14/26 8:00:00 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    SEC Filings

    View All

    CVRx Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - CVRx, Inc. (0001235912) (Filer)

    6/3/26 4:49:03 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by CVRx Inc.

    SD - CVRx, Inc. (0001235912) (Filer)

    5/28/26 5:06:16 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by CVRx Inc.

    10-Q - CVRx, Inc. (0001235912) (Filer)

    5/12/26 8:00:37 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jain Mudit K. bought $297,592 worth of shares (46,800 units at $6.36) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/23/26 6:00:12 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Jain Mudit K. bought $2,785 worth of shares (600 units at $4.64), increasing direct ownership by 12% to 5,650 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    2/18/26 5:22:25 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Nielsen Kirk G. bought $59,795 worth of shares (10,966 units at $5.45) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    5/19/25 6:46:37 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CVRx, Inc. downgraded by Analyst with a new price target

    Analyst downgraded CVRx, Inc. from Neutral to Underweight and set a new price target of $7.00

    5/9/25 8:41:10 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx, Inc. upgraded by William Blair

    William Blair upgraded CVRx, Inc. from Mkt Perform to Outperform

    1/14/25 7:51:14 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Cantor Fitzgerald initiated coverage on CVRx, Inc. with a new price target

    Cantor Fitzgerald initiated coverage of CVRx, Inc. with a rating of Overweight and set a new price target of $14.00

    9/10/24 7:46:21 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Nielsen Kirk G. was granted 8,720 shares (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    6/3/26 6:06:47 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Jain Mudit K. was granted 8,720 shares, increasing direct ownership by 154% to 14,370 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    6/3/26 6:06:22 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Slattery Joseph P was granted 8,720 shares, increasing direct ownership by 28% to 39,365 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    6/3/26 6:05:58 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Leadership Updates

    Live Leadership Updates

    View All

    CVRx Announces Nomination of Michael Dale for Election to the Board of Directors

    MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the nomination of Michael Dale to serve on its Board of Directors. Mr. Dale will stand for election at the annual meeting of stockholders scheduled for June 1, 2026. "Michael has achieved an outstanding record of commercial success in the medical device industry, and I'm excited for him to join our Board of Directors," said Kevin Hykes, President and CEO of CVRx. "His extensive experience leading high growth organizations, both as an executi

    4/20/26 4:30:00 PM ET
    $AXGN
    $CVRX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer

    MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States. "We are thrilled to welcome Robert to the CVRx executive team as we continue to expand the adoption of Barostim therapy," said Kevin Hykes, President and CEO of CVRx. "Robert is well-known and respected within the heart failure community and

    6/25/24 6:50:00 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer

    Appointment effective February 12 following Nadim Yared's retirement Hykes currently serves as Augmedics' President and CEO, and has served on CVRx's Board of Directors since 2022 MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company's new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company's Board of Directors. Yared will retire from the Company and resign his Board seat concurrent with Hykes' appointment and has agreed to consult with the Company to ensure a seamless transition. Hykes is an accomplishe

    1/31/24 8:00:00 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Financials

    Live finance-specific insights

    View All

    CVRx Reports First Quarter 2026 Financial and Operating Results

    MINNEAPOLIS, May 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2026. Recent Highlights Total revenue for the first quarter of 2026 was $14.8 million, an increase of approximately 20% over the prior year quarterU.S. revenue for the first quarter of 2026 was $13.7 million, an increase of 22% over the prior year quarterActive implanting centers in the U.S. grew to 257 as of March 31, 2026, as compared to 227 as of March 3

    5/11/26 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026

    MINNEAPOLIS, April 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release first quarter 2026 financial and operating results after market close on Monday, May 11, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, p

    4/27/26 4:30:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2025. Recent Highlights Total revenue for the fourth quarter 2025 was $16.0 million, an increase of 4% over the prior year quarterU.S. revenue for the fourth quarter of 2025 was $14.9 million, an increase of 4% over the prior year quarterTotal revenue for 2025 was $56.7 million, an increase of 10% over the prior yearActive implanting centers

    2/12/26 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by CVRx Inc.

    SC 13D/A - CVRx, Inc. (0001235912) (Subject)

    11/7/24 9:10:51 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by CVRx Inc.

    SC 13G/A - CVRx, Inc. (0001235912) (Subject)

    11/1/24 11:05:15 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by CVRx Inc. (Amendment)

    SC 13G/A - CVRx, Inc. (0001235912) (Subject)

    2/6/24 7:56:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care